Affimed N.V. (AFMD)
| Previous Close | 2.0600 |
| Open | 2.0800 |
| Bid | 2.0100 x 2200 |
| Ask | 2.0200 x 3200 |
| Day's Range | 2.0000 - 2.1000 |
| 52 Week Range | 1.9300 - 7.3500 |
| Volume | |
| Avg. Volume | 1,003,609 |
| Market Cap | 299.425M |
| Beta (5Y Monthly) | 2.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6590 |
| Earnings Date | Oct 27, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.49 |
- Simply Wall St.
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable patients in an unselected patient populationComprehensive pharmacodynamic studies indicate the activation of the innate as well as the adaptive immune systemWell managed safety profile HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology com
- GlobeNewswire
Affimed to Present at Upcoming Investor Conferences
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of September 2022. 2022 Wells Fargo Healthcare Conference (September 6-9, 2022)Date: Wednesday, September 7, 2022Presentation Time: 3:10 p.m. Eastern Dayli
